Bionano Genomics (BNGO) Net Income towards Common Stockholders (2017 - 2026)
Bionano Genomics (BNGO) posted Net Income towards Common Stockholders of -$8.3 million for Q1 2026, down 144.84% sequentially from $18.5 million in Q4 2025, and down 167.67% YoY from $12.3 million in Q1 2025.
Bionano Genomics (BNGO) Net Income towards Common Stockholders (2017 - 2026) Analysis & Trends
Bionano Genomics has reported Net Income towards Common Stockholders for 10 years, with the latest figure at -$8.3 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 167.67% year-over-year to -$8.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5.1 million (up 93.88% YoY) and the FY2025 annual result came in at $55000.0, up 100.05% from the prior year.
- Net Income towards Common Stockholders slipped to -$8.3 million in Q1 2026 per BNGO's latest filing, from $18.5 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $18.5 million in Q4 2025 and troughed at -$112.6 million in Q3 2023.
- A 5-year average of -$28.6 million and a median of -$31.4 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2023 and 2025: Net Income towards Common Stockholders sank 253.88% in 2023, then soared 190.51% in 2025.
- Over 5 years, Net Income towards Common Stockholders stood at -$38.7 million in 2022, then slipped by 13.48% to -$43.9 million in 2023, then jumped by 53.39% to -$20.5 million in 2024, then jumped by 190.51% to $18.5 million in 2025, then plunged by 144.84% to -$8.3 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$8.3 million, $18.5 million, and -$8.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 132.71 Bn | 127.50 Bn | 1.96 Bn | 823.20 Mn |
| 2 | Becton Dickinson | 51.57 Bn | 50.71 Bn | 2.32 Bn | 378.00 Mn |
| 3 | Alcon | 35.52 Bn | 34.17 Bn | 1.68 Bn | - |
| 4 | Resmed | 33.28 Bn | 31.81 Bn | 861.22 Mn | 383.43 Mn |
| 5 | Medline | 27.86 Bn | 25.18 Bn | 2.22 Bn | 139.00 Mn |
| 6 | West Pharmaceutical Services | 25.15 Bn | 24.71 Bn | 329.20 Mn | 147.90 Mn |
| 7 | Solventum | 15.31 Bn | 14.91 Bn | 1.29 Bn | 93.00 Mn |
| 8 | Cooper Companies | 14.86 Bn | 14.72 Bn | 735.40 Mn | -77.90 Mn |
| 9 | Baxter International | 13.63 Bn | 11.48 Bn | 1.03 Bn | 126.00 Mn |
| 10 | Bionano Genomics | 14.03 Mn | 4.10 Mn | 4.31 Mn | -7.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.42 Mn |
| Mar 31, 2026 | -8.30 Mn |
| Dec 31, 2025 | 18.52 Mn |
| Sep 30, 2025 | -8.50 Mn |
| Jun 30, 2025 | -6.86 Mn |
| Mar 31, 2025 | -3.10 Mn |
| Dec 31, 2024 | -20.46 Mn |
| Sep 30, 2024 | -44.25 Mn |
| Jun 30, 2024 | -16.22 Mn |
| Mar 31, 2024 | -31.42 Mn |
| Dec 31, 2023 | -43.89 Mn |
| Sep 30, 2023 | -112.57 Mn |
| Jun 30, 2023 | -38.91 Mn |
| Mar 31, 2023 | -37.12 Mn |
| Dec 31, 2022 | -38.68 Mn |
| Sep 30, 2022 | -31.81 Mn |
| Jun 30, 2022 | -32.16 Mn |
| Mar 31, 2022 | -29.95 Mn |
| Dec 31, 2021 | -22.95 Mn |
| Sep 30, 2021 | -20.75 Mn |